Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis
A new tuberculosis drug combination shows promise against resistant strains with acceptable safety in early human testing.
A new drug combination approach for tuberculosis pairs the clinical candidate alpibectir with ethionamide to enhance antibacterial activity, even against resistant strains. Alpibectir completed Phase 1 with a clean safety profile.
What the study was
- Study design
- Preclinical + Phase 1 safety
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature Communications
Why it surfaced
Novel TB combination therapy with Phase 1 safety data; high unmet need in drug-resistant TB. Unsolicited find outside watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.